A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years

A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years

Abstract Background A previous phase 2 study demonstrated the immunogenicity of a single dose of meningococcal A, C, W, Y-tetanus toxoid conjugate (MenACWY-TT) or polysaccharide (MenACWY-PS) vaccine for up to 5 years in individuals aged 11–55 years. This follow-up study evaluated long-term antibody...

Full description

Bibliographic Details
Main Authors: Charissa Fay Corazon Borja-Tabora, Paula Peyrani, Chris Webber, Marie Van der Wielen, Brigitte Cheuvart, Nathalie De Schrevel, Veronique Bianco, Emmanuel Aris, Mark Cutler, Ping Li, John L. Perez
Format: Article
Language:English
Published: BMC 2020-06-01
Series:BMC Infectious Diseases
Subjects:
Antibody
Immunogenicity
MenACWY-TT
Meningococcal
Persistence
Booster
Online Access:http://link.springer.com/article/10.1186/s12879-020-05104-5

Internet

http://link.springer.com/article/10.1186/s12879-020-05104-5

Similar Items